CAVALLA, Paola
 Distribuzione geografica
Continente #
NA - Nord America 1.444
EU - Europa 1.153
AS - Asia 552
SA - Sud America 80
OC - Oceania 24
AF - Africa 12
Totale 3.265
Nazione #
US - Stati Uniti d'America 1.378
IT - Italia 301
CN - Cina 167
SE - Svezia 123
DE - Germania 116
SG - Singapore 101
IE - Irlanda 99
GB - Regno Unito 89
JP - Giappone 87
FR - Francia 83
TW - Taiwan 64
AT - Austria 60
CA - Canada 58
BR - Brasile 53
ES - Italia 50
NL - Olanda 42
IN - India 39
UA - Ucraina 35
FI - Finlandia 30
PT - Portogallo 29
GR - Grecia 24
AU - Australia 23
BE - Belgio 21
HK - Hong Kong 15
CO - Colombia 13
TR - Turchia 13
IR - Iran 12
ID - Indonesia 10
KR - Corea 10
VN - Vietnam 9
CH - Svizzera 8
NO - Norvegia 8
SN - Senegal 8
AR - Argentina 7
MX - Messico 7
PL - Polonia 7
RO - Romania 7
CZ - Repubblica Ceca 6
DK - Danimarca 6
IL - Israele 6
PH - Filippine 5
CL - Cile 4
PS - Palestinian Territory 3
SA - Arabia Saudita 3
TH - Thailandia 3
IS - Islanda 2
LB - Libano 2
NG - Nigeria 2
NP - Nepal 2
RU - Federazione Russa 2
UY - Uruguay 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CY - Cipro 1
EC - Ecuador 1
EE - Estonia 1
LV - Lettonia 1
MA - Marocco 1
NZ - Nuova Zelanda 1
SI - Slovenia 1
SV - El Salvador 1
ZA - Sudafrica 1
Totale 3.265
Città #
Chandler 130
Santa Clara 118
Dublin 94
Singapore 89
Beijing 83
Turin 80
Redwood City 76
Ashburn 49
Torino 49
Villeurbanne 49
Taipei 45
Fairfield 44
Houston 41
Vienna 40
Ann Arbor 33
Medford 29
Wilmington 29
Nyköping 24
Seattle 24
Chicago 22
Princeton 22
Woodbridge 22
Columbus 21
Dearborn 19
New York 16
Toronto 16
Tokyo 15
London 14
Redhill 14
Lisbon 13
Boston 12
Jacksonville 12
Pisa 12
Cambridge 11
Guangzhou 11
Leipzig 11
Athens 10
Boardman 10
Los Angeles 10
Milan 10
Ottawa 10
Chengdu 9
Lleida 9
Nijmegen 9
Oklahoma City 9
Saint Louis 9
Berlin 8
Bogotá 8
Osaka 8
Brussels 7
Fremont 7
Helsinki 7
New Taipei City 7
Paris 7
Rome 7
Barcelona 6
Boulder 6
Brisbane 6
Brooklyn 6
Central 6
Duncan 6
Köln 6
Milwaukee 6
Regensburg 6
São Paulo 6
Warsaw 6
Bello 5
Belo Horizonte 5
Bethesda 5
Bollate 5
Champaign 5
Clemson 5
Delhi 5
Edmonton 5
Hefei 5
Jakarta 5
Lund 5
Portland 5
Valencia 5
Wynnewood 5
Chennai 4
Falls Church 4
Genoa 4
Guaymallen 4
Innsbruck 4
Izmir 4
Limerick 4
Munich 4
Nanjing 4
Naples 4
New Haven 4
Nishikicho 4
Olomouc 4
Padova 4
Recife 4
San Diego 4
Santa Eugenia De Berga 4
Skövde 4
South Shields 4
Uppsala 4
Totale 1.766
Nome #
Specialist palliative care improves the quality of life in advanced neurodegenerative disorders: NE-PAL, a pilot randomised controlled study 1.521
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 184
Inflammatory responses in Multiple Sclerosis normal-appearing white matter and in non-immune mediated neurological conditions with wallerian axonal degeneration: A comparative study 181
Role of multiple sclerosis treatment on neutrophil multifaceted functions against bacteria. 142
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP 118
NEW INSIGHTS INTO THE ROLE OF MULTIPLE SCLEROSIS TREATMENT ON POLYMORPHONUCLEAR LEUKOCYTE FUNCTIONS AGAINST PATHOGENS 94
F-box protein Skp2 is not the only pathway for p27/Kip.1 degradation 87
Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study 78
Neurodegeneration and iron accumulation in deep grey matter nuclei in multiple sclerosis. 77
The phagocyte functional impairment in treated multiple sclerosis patients. 75
How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial 66
Cyclins, CDKs and their inhibitor p27/Kip.1 in normal and neoplastic oligodendroglia 64
p14ARF/Mdm2/p53 pathway deregulation in two glioblastoma series: with and without differentiated areas 61
Cyclins D1 and p27/Kip.1 in the differential diagnosis of diffuse astrocytomas and oligodendrogliomas 60
The recognition of different pathways to apoptosis in gliomas migth have different biological significances 58
p27/Kip.1 ubiquitin ligase subunit skp2 relationships with cell proliferation and p27/Kip.1 expression in gliomas 56
Cyclins and CDKs in classic and anaplastic oligodendroglioma 55
The uncertain definitions of oligodendrogliomas influence the evaluation of the efficacy of therapies 51
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 51
The role of caspase-3 in the pathways to apoptosis in gliomas 50
Relationship between apoptosis and caspase 3 expression in malignant gliomas 49
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 48
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 33
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 31
Risk of Getting COVID-19 in People With Multiple Sclerosis 14
A real‐world study of alemtuzumab in a cohort of Italian patients 13
Acute and chronic synaptic pathology in multiple sclerosis gray matter 11
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 9
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study 8
CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab 7
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study 7
Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience 6
Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells 5
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 4
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study 4
Prevalence and patterns of subclinical motor and cognitive impairments in non-disabled individuals with early multiple sclerosis: A multicenter cross-sectional study 4
Totale 3.382
Categoria #
all - tutte 8.019
article - articoli 0
book - libri 0
conference - conferenze 3.813
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.832


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020241 0 0 0 0 0 35 49 26 23 54 36 18
2020/2021398 33 14 25 39 30 48 35 21 51 24 30 48
2021/2022495 22 36 33 45 33 32 36 21 33 55 99 50
2022/2023550 41 30 23 43 62 107 45 40 72 23 32 32
2023/2024313 43 55 25 23 23 30 22 14 14 10 31 23
2024/2025506 27 25 38 73 178 165 0 0 0 0 0 0
Totale 3.382